Free Trial

SciSparc (SPRC) Competitors

SciSparc logo
$6.82 +0.31 (+4.74%)
Closing price 07/3/2025 03:38 PM Eastern
Extended Trading
$7.00 +0.17 (+2.55%)
As of 07/3/2025 04:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SPRC vs. IMNN, FLGC, ERNA, ASBP, TXMD, ME, NEUP, ALVR, ABP, and NXTC

Should you be buying SciSparc stock or one of its competitors? The main competitors of SciSparc include Imunon (IMNN), Flora Growth (FLGC), Ernexa Therapeutics (ERNA), Aspire Biopharma (ASBP), TherapeuticsMD (TXMD), 23andMe (ME), Neuphoria Therapeutics (NEUP), AlloVir (ALVR), Abpro (ABP), and NextCure (NXTC). These companies are all part of the "pharmaceutical products" industry.

SciSparc vs. Its Competitors

SciSparc (NASDAQ:SPRC) and Imunon (NASDAQ:IMNN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, media sentiment, valuation, earnings and analyst recommendations.

In the previous week, Imunon had 3 more articles in the media than SciSparc. MarketBeat recorded 4 mentions for Imunon and 1 mentions for SciSparc. SciSparc's average media sentiment score of 0.00 beat Imunon's score of -0.02 indicating that SciSparc is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
SciSparc
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Imunon
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

SciSparc has a beta of 0.72, meaning that its share price is 28% less volatile than the S&P 500. Comparatively, Imunon has a beta of 1.93, meaning that its share price is 93% more volatile than the S&P 500.

25.1% of SciSparc shares are owned by institutional investors. Comparatively, 4.5% of Imunon shares are owned by institutional investors. 1.5% of SciSparc shares are owned by company insiders. Comparatively, 6.0% of Imunon shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Imunon has a consensus price target of $15.50, indicating a potential upside of 1,859.54%. Given Imunon's stronger consensus rating and higher possible upside, analysts plainly believe Imunon is more favorable than SciSparc.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SciSparc
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Imunon
0 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.75

SciSparc has higher revenue and earnings than Imunon.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SciSparc$1.31M2.76-$6.28MN/AN/A
Imunon$500K27.75-$18.62M-$1.36-0.58

SciSparc's return on equity of 0.00% beat Imunon's return on equity.

Company Net Margins Return on Equity Return on Assets
SciSparcN/A N/A N/A
Imunon N/A -427.98%-175.03%

Summary

Imunon beats SciSparc on 8 of the 14 factors compared between the two stocks.

Get SciSparc News Delivered to You Automatically

Sign up to receive the latest news and ratings for SPRC and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SPRC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SPRC vs. The Competition

MetricSciSparcMED IndustryMedical SectorNASDAQ Exchange
Market Cap$3.53M$2.43B$5.55B$9.04B
Dividend YieldN/A1.67%5.22%3.99%
P/E RatioN/A9.3527.6620.24
Price / Sales2.76691.51419.21118.06
Price / CashN/A158.5936.8958.10
Price / Book0.384.588.035.67
Net Income-$6.28M$31.34M$3.18B$249.21M
7 Day Performance5.52%3.25%2.93%3.28%
1 Month Performance2.85%3.46%1.72%3.95%
1 Year Performance-56.78%0.77%34.39%20.98%

SciSparc Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SPRC
SciSparc
0.4563 of 5 stars
$6.83
+4.7%
N/A-56.8%$3.53M$1.31M0.004Stock Split
IMNN
Imunon
2.1008 of 5 stars
$0.79
-1.4%
$15.50
+1,864.5%
-41.8%$14.01M$500K-0.5930News Coverage
Analyst Upgrade
FLGC
Flora Growth
3.0115 of 5 stars
$0.62
+6.2%
$4.00
+549.4%
-31.0%$13.90M$59.51M-0.63280News Coverage
ERNA
Ernexa Therapeutics
N/A$1.83
-0.8%
N/A-93.1%$13.84M$580K-0.2310
ASBP
Aspire Biopharma
N/A$0.27
+1.1%
N/AN/A$13.47MN/A0.00N/A
TXMD
TherapeuticsMD
0.8397 of 5 stars
$1.01
-13.1%
N/A-25.8%$13.46M$1.76M0.00420Gap Up
ME
23andMe
N/A$0.50
-35.3%
N/A-94.2%$13.36M$208.78M-0.03770Gap Down
High Trading Volume
NEUP
Neuphoria Therapeutics
1.3276 of 5 stars
$7.10
+1.4%
$21.00
+195.8%
N/A$13.35M$10K0.00N/A
ALVR
AlloVir
N/A$2.62
+2.3%
N/A-84.5%$13.21MN/A-0.13110Gap Up
High Trading Volume
ABP
Abpro
N/A$0.21
-1.2%
$4.00
+1,802.0%
N/A$12.78M$180K0.0015
NXTC
NextCure
4.1242 of 5 stars
$0.46
+1.1%
$3.50
+669.2%
-70.7%$12.76MN/A-0.2690Analyst Forecast
High Trading Volume

Related Companies and Tools


This page (NASDAQ:SPRC) was last updated on 7/6/2025 by MarketBeat.com Staff
From Our Partners